DevelopmentsProduct News

Dasatinib Clonmel

Clonmel Healthcare is delighted to announce the launch of Dasatinib Clonmel 20mg, 50mg, 70mg and 100mg Film-coated Tablets.

Dasatinib Clonmel is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy.

Full prescribing information is available on request or alternatively please go to www.clonmel-health.ie.  Medicinal product subject to medical prescription.

Please contact Clonmel Healthcare on 01-6204000 if you require any additional information.

PA 0126/310/001-004. PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary. Date prepared: April 2020. 2020/ADV/DAS/036H

Show More

Related Articles

Close

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?